125 related articles for article (PubMed ID: 37168400)
1. Effects of visceral adipose tissue on anti-tumour necrosis factor-α in Crohn's disease.
Li K; Gong P; Zhang Y; Liu M; Zhang Z; Yu X; Ye M; Tian L
Therap Adv Gastroenterol; 2023; 16():17562848231171962. PubMed ID: 37168400
[TBL] [Abstract][Full Text] [Related]
2. Visceral adiposity and inflammatory bowel disease.
Rowan CR; McManus J; Boland K; O'Toole A
Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
[TBL] [Abstract][Full Text] [Related]
3. Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn's disease under infliximab therapy.
Cao WT; Huang R; Liu S; Fan YH; Xu MS; Xu Y; Ni H
World J Gastroenterol; 2022 Jun; 28(23):2582-2596. PubMed ID: 35949356
[TBL] [Abstract][Full Text] [Related]
4. Serum Infliximab, Antidrug Antibodies, and Tumor Necrosis Factor Predict Sustained Response in Pediatric Crohn's Disease.
Stein R; Lee D; Leonard MB; Thayu M; Denson LA; Chuang E; Herskovitz R; Kerbowski T; Baldassano RN
Inflamm Bowel Dis; 2016 Jun; 22(6):1370-7. PubMed ID: 27057683
[TBL] [Abstract][Full Text] [Related]
5. CT-based radiomics signature of visceral adipose tissue and bowel lesions for identifying patients with Crohn's disease resistant to infliximab.
Wang Y; Luo Z; Zhou Z; Zhong Y; Zhang R; Shen X; Huang L; He W; Lin J; Fang J; Huang Q; Wang H; Zhang Z; Mao R; Feng ST; Li X; Huang B; Li Z; Zhang J; Chen Z
Insights Imaging; 2024 Jan; 15(1):28. PubMed ID: 38289416
[TBL] [Abstract][Full Text] [Related]
6. The Effect of Adiposity on Anti-Tumor Necrosis Factor-Alpha Levels and Loss of Response in Crohn's Disease Patients.
Lim Z; Welman CJ; Raymond W; Thin L
Clin Transl Gastroenterol; 2020 Sep; 11(9):e00233. PubMed ID: 33094963
[TBL] [Abstract][Full Text] [Related]
7. Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease.
Beltrán B; Iborra M; Sáez-González E; Marqués-Miñana MR; Moret I; Cerrillo E; Tortosa L; Bastida G; Hinojosa J; Poveda-Andrés JL; Nos P
Dig Dis; 2019; 37(2):108-115. PubMed ID: 30149385
[TBL] [Abstract][Full Text] [Related]
8. CT-based radiomics signature of visceral adipose tissue for prediction of disease progression in patients with Crohn's disease: A multicentre cohort study.
Li X; Zhang N; Hu C; Lin Y; Li J; Li Z; Cui E; Shi L; Zhuang X; Li J; Lu J; Wang Y; Liu R; Yuan C; Lin H; He J; Ke D; Tang S; Zou Y; He B; Sun C; Chen M; Huang B; Mao R; Feng ST
EClinicalMedicine; 2023 Feb; 56():101805. PubMed ID: 36618894
[TBL] [Abstract][Full Text] [Related]
9. Visceral Adipose Tissue Volumetrics Inform Odds of Treatment Response and Risk of Subsequent Surgery in IBD Patients Starting Antitumor Necrosis Factor Therapy.
Gu P; Chhabra A; Chittajallu P; Chang C; Mendez D; Gilman A; Fudman DI; Xi Y; Feagins LA
Inflamm Bowel Dis; 2022 May; 28(5):657-666. PubMed ID: 34291800
[TBL] [Abstract][Full Text] [Related]
10. Cytokine Profile at Diagnosis Affecting Trough Concentration of Infliximab in Pediatric Crohn's Disease.
Kwon Y; Kim ES; Kim YZ; Choe YH; Kim MJ
Biomedicines; 2022 Sep; 10(10):. PubMed ID: 36289634
[TBL] [Abstract][Full Text] [Related]
11. The Appropriateness Criteria of Abdominal Fat Measurement at the Level of the L1-L2 Intervertebral Disc in Patients With Obesity.
Sun J; Lv H; Zhang M; Li M; Zhao L; Zeng N; Liu Y; Wei X; Chen Q; Ren P; Liu Y; Zhang P; Yang Z; Zhang Z; Wang Z
Front Endocrinol (Lausanne); 2021; 12():784056. PubMed ID: 34970225
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of bone mineral density and body compositions interrelation in young and middle-aged male patients with Crohn's disease by quantitative computed tomography.
Zhang X; Peng K; Li G; Wan L; Xu T; Cui Z; Xiao F; Li L; Liu Z; Zhang L; Tang G
Front Endocrinol (Lausanne); 2022; 13():953289. PubMed ID: 36213271
[TBL] [Abstract][Full Text] [Related]
13. Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn's disease patients.
Strik AS; Löwenberg M; Buskens CJ; B Gecse K; I Ponsioen C; Bemelman WA; D'Haens GR
Scand J Gastroenterol; 2019 Apr; 54(4):453-458. PubMed ID: 31032686
[No Abstract] [Full Text] [Related]
14. Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease.
Roblin X; Duru G; Williet N; Del Tedesco E; Cuilleron M; Jarlot C; Phelip JM; Boschetti G; Flourié B; Nancey S; Peyrin-Biroulet L; Paul S
Inflamm Bowel Dis; 2017 Jan; 23(1):126-132. PubMed ID: 28002129
[TBL] [Abstract][Full Text] [Related]
15. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF.
Yamada A; Sono K; Hosoe N; Takada N; Suzuki Y
Inflamm Bowel Dis; 2010 Nov; 16(11):1898-904. PubMed ID: 20310016
[TBL] [Abstract][Full Text] [Related]
16. Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment.
Imaeda H; Bamba S; Takahashi K; Fujimoto T; Ban H; Tsujikawa T; Sasaki M; Fujiyama Y; Andoh A
J Gastroenterol; 2014 Apr; 49(4):674-82. PubMed ID: 23666424
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Infliximab Therapy in Children with Crohn's Disease Using Trough Levels Predictors.
Ohem J; Hradsky O; Zarubova K; Copova I; Bukovska P; Prusa R; Malickova K; Bronsky J
Dig Dis; 2018; 36(1):40-48. PubMed ID: 28817809
[TBL] [Abstract][Full Text] [Related]
18. One-Year Clinical Outcomes in an IBD Cohort Who Have Previously Had Anti-TNFa Trough and Antibody Levels Assessed.
Tighe D; Hall B; Jeyarajah SK; Smith S; Breslin N; Ryan B; McNamara D
Inflamm Bowel Dis; 2017 Jul; 23(7):1154-1159. PubMed ID: 28486256
[TBL] [Abstract][Full Text] [Related]
19. Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn's disease: systematic reviews and economic modelling.
Freeman K; Connock M; Auguste P; Taylor-Phillips S; Mistry H; Shyangdan D; Court R; Arasaradnam R; Sutcliffe P; Clarke A
Health Technol Assess; 2016 Nov; 20(83):1-288. PubMed ID: 27845027
[TBL] [Abstract][Full Text] [Related]
20. Isolated Crohn's Colitis: Is Localization Crucial? Characteristics of Pediatric Patients From the CEDATA-GPGE Registry.
Elonen L; Wölfle L; de Laffolie J; Posovszky C;
Front Pediatr; 2022; 10():875938. PubMed ID: 35712614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
